linjc16/ctgov huggingface dataset:
Treatment of Asymptomatic Toxocariasis With Albendazole in Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate effectiveness of albendazole in the treatment of the asymptomatic infection with the parasite Toxocara in children. Treatment response is defined as a reduction in the number of eosinophils in blood. The study drug will be compared to placebo and randomly assigned in a double blind manner. Follow up will be prospective. 50 children (25 per group) will be enrolled in the study.

Official Title
-----------------
Treatment of Asymptomatic Toxocariasis With Albendazole in Children. A Prospective, Randomized, Placebo-controlled Clinical Trial

Conditions
-----------------
Toxocariasis

Intervention / Treatment
-----------------
* Drug: Albendazole
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric ambulatory patients with asymptomatic toxocariasis Children 2 - 15 years old Absolute eosinophil count > 1100 / mm3 Normal ophthalmoscopy Exclusion Criteria: Treatment with a benzimidazole in the previous year Infection by other nematodes (Ascaris lumbricoides, strongyloides stercoralis, uncinarias, Trichuris trichuria) Symptomatic patients (prolonged fever, acute pneumonitis, hepatomegaly, splenomegaly, ocular compromise due to toxocara) Concomitant diseases Immunocompromised patients Altered liver or kidney function Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Albendazole<br>Albendazole 10 - 15 mg/kg/day BID for 15 days | Drug: Albendazole<br>* Albendazole 10 - 15 mg/kg/day BID for 15 days<br>|
| Placebo Comparator: Placebo<br>Placebo BID for 15 days | Drug: Placebo<br>* Placebo BID for 15 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean absolute reduction in eosinophil count from baseline |  | 12 months after treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in eosinophil count in more than 60% from baseline |  | 1 year | 
| Incidence of adverse drug events |  | 3, 6, 9 and 12 months after treatment | 
| Mean absolute reduction in eosinophil count |  | 3, 6, 9 months after treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Toxocara, Pediatrics, Albendazole, eosinophilia, parasitology, pediatric clinical pharmacology
DEXAMETHASONE for Non-urgent Thoracic Surgery

Study Overview
=================
Brief Summary
-----------------
Thoracic surgery is at high risk of respiratory complications. Despite the improvement of surgical procedures such as video-thoracoscopy, respiratory complications appear in 15 to -20% of procedures. Thoracic surgery induces local pulmonary inflammation which is involved in the occurrence of post-operative respiratory failure. Similarly to the example of the acute respiratory distress syndrome, corticosteroids could reduce lung injury secondary to immunological stress. In addition, recent studies suggest that dexamethasone could lead to a reduction of respiratory complications after major non cardiothoracic surgery. Since dexamethasone is recommended to prevent postoperative nausea and vomiting, around one in two patients receive dexamethasone during anesthetic induction. By retrospective analysis with compensation of bias by propensity score, the investigators aim to assess the effect of dexamethasone to prevent respiratory complications

Official Title
-----------------
Assessment of DEXAMETHASONE to Prevent Respiratory Complications After Non Urgent Thoracic Surgery

Conditions
-----------------
Thoracic Surgery, Anesthesiology, Corticosteroids, Respiratory Complication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age : minimum 18 years old Patients who underwent scheduled lung resection surgery Exclusion Criteria: absence of patient's consent age under 18 years pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of respiratory failure rates between patients receiving or not DEXAMETHASONE |  | 7 days following surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thoracic surgery, Anesthesiology, Corticosteroids, Respiratory Complication
Chemsex Engagement and HIV Biomedical Prevention in MSM

Study Overview
=================
Brief Summary
-----------------
HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

Official Title
-----------------
The Interrelationship Between Chemsex Engagement and HIV Biomedical Prevention in MSM

Conditions
-----------------
Recreational Drug Use

Intervention / Treatment
-----------------
* Diagnostic Test: HIV test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18 or above male have had sex with men since 2019 could be communicated in English or Chinese Exclusion Criteria: failed to provide consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HIV-negative<br> | Diagnostic Test: HIV test<br>* HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status<br>|
| HIV-positive<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pre-exposure prophylaxis coverage | proportion of HIV-negative MSM taking pre-exposure prophylaxis; based on self-reported data in questionnaire | 6 months | 
| Good antiretroviral therapy adherence | proportion of HIV-positive MSM with good antiretroviral therapy adherence; based on self-reported data (CD4 count, viral load level, history of stoppoing ART / missing doses) in questionnaire | 2 years | 
| Drug use pattern | types of drugs taken for chemsex engagement (taking before or during sex); based on self-reported data in questionnaire | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chemsex engagement, Pre-exposure prophylaxis, Antiretroviral therapy, men who have sex with men
miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi

Study Overview
=================
Brief Summary
-----------------
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study, the investigators examines the expression profiles of miRNA machinery components such as miRNA maturation and transport factors, microprocessor complex and RISC subunits in cutaneous melanoma, cutaneous melanoma metastases and benign melanocytic nevi.

Detailed Description
-----------------
Patients with cutaneous melanoma, cutaneous melanoma metastases and benign melanocytic nevi were included in the study. Punch biopsies were harvested from the center of the tumors. The miRNA machinery components were detected by quantitative real-time reverse transcriptase polymerase chain reaction.

Official Title
-----------------
The miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi

Conditions
-----------------
Cutaneous Melanoma, Nevi

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cutaneous melanoma cutaneous melanoma metastases benign melanocytic nevi Exclusion Criteria: other forms of malignancy

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cutaneous Melanoma<br> | |
| Cutaneous Melanoma Metastases<br> | |
| Benign Melanocytic Nevi<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Study Overview
=================
Brief Summary
-----------------
This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.

Detailed Description
-----------------
No sampling as no subjects are enrolled

Official Title
-----------------
A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use

Conditions
-----------------
Invasive Pneumococcal Disease

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S pneumoniae from a normally sterile site in a member of the surveillance population. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of IPD in the NCKP healthcare system in children 6 weeks through 5 years of age (prior to the sixth birthday) during each of the 5 years following introduction of Prevnar 13. |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pneumococcal conjugate vaccine
Chronic Inflammation and Exercise Responsiveness

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine how chronic inflammation influences skeletal muscle protein metabolism and metabolic function in humans. The investigators will evaluate acute responsiveness to a single bout of exercise in men and women who are either lean or overweight/obese. The investigators will explore the relationship between circulating inflammatory markers and anabolic, proteomic, and transcriptional responses to acute exercise. The investigators will measure skeletal muscle protein synthesis in the postabsorptive state and in response to a single bout of exercise.

Official Title
-----------------
Chronic Inflammation and Exercise Responsiveness

Conditions
-----------------
Metabolic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 30-55 years BMI 19-45 kg/m2 Exclusion Criteria: Anemia (female subjects hemoglobin of <11 g/dl and male subjects hemoglobin <12 g/dl) Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment) Renal insufficiency/failure (serum creatinine > 1.5mg/dl) Oral warfarin group medications or history of blood clotting disorders. Pregnancy or breastfeeding Alcohol consumption greater than 2 glasses/day or other substance abuse Untreated or uncontrolled thyroid disorders Debilitating chronic disease (at the discretion of the investigators)

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lean<br>Body mass index less than 25 kg/m2 | |
| Overweight/obese<br>Body mass index 25-45 kg/m2 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximal oxygen consumption rates in mitochondria isolated from skeletal muscles |  | 1 day |
Positive End-expiratory Pressure and Alveolar Recruitment for One Lung Ventilation

Study Overview
=================
Brief Summary
-----------------
Hypoxia frequently develops during one lung ventilation in the supine position.The objective of this article is to study the impact of preemptive alveolar recruitment and subsequent positive end expiratory pressure on arterial oxygenation and lung mechanics during one lung ventilation in the supine position in patients undergoing thoracic surgery .

Detailed Description
-----------------
outcome measures: respiratory parameters (Paw, Ppla, Compliance, Vd/Vt)and oxygenation parameters (PaO2, shunt fraction, Pa-AO2)

Official Title
-----------------
Effects of Positive End-expiratory Pressure and Alveolar Recruitment on the Oxygenation and Respiratory Mechanics During One-lung Ventilation in the Supine Position

Conditions
-----------------
One Lung Ventilation

Intervention / Treatment
-----------------
* Other: PEEP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-II age: 20-75 years Exclusion Criteria: moderate to severe impaired respiratory function, heart failure, patients' refusal

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>zero PEEP | |
| Experimental: OLV strategy: PEEP<br>1. apply 8 cm H2O positive end expiratory pressure during one lung ventilation and until the end of surgery | Other: PEEP<br>* 8 cmH2O PEEP throughout the period of OLV and 2nd TLV<br>|
| Experimental: OLV strategy: PEEP followed by AR<br>alveolar recruitment strategy before one lung ventilation 8 cmH2O positive end expiratory pressure during one lung ventilation and until the end of surgery | Other: PEEP<br>* 8 cmH2O PEEP throughout the period of OLV and 2nd TLV<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PaO2, number of patients with hypoxia (PaO2< 90mmHg) | blood samplings after induction of anesthesia, 15 and 30 min after OLV, after the 2nd TLV | participants will be followed for the duration of anesthesia, an expected average of 3 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intrapulmonary shunt | blood sampling after induction of anesthesia, 15 and 30 min after OLV, after the 2nd TLV | participants will be followed for the duration of anesthesia, an expected average of 3 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
positive end expiratory pressure
Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy

Study Overview
=================
Brief Summary
-----------------
This is a randomized controlled pilot study investigating signals involved in drug resistance to chemotherapy. Patient will be randomized to undergo observation or to receive Everolimus after completion of neoadjvuant treatment (anthracycline and/or taxane-based) and before surgery. The patients will be monitored for efficacy and safety.

Official Title
-----------------
A Randomized Study of mTOR Inhibition by RAD001 (Everolimus) in Invasive Breast Cancer Patients After Pre-operative Use of Anthracycline and/or Taxane-based Chemotherapy

Conditions
-----------------
Breast Neoplasms

Intervention / Treatment
-----------------
* Drug: Everolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged ≥ 18 years; Histologically and/or cytologically confirmed invasive ductal or lobular breast cancer; Tumor of 3 cm or greater at time of diagnosis Measurable primary tumor after neoadjuvant treatment before randomization No prior chemotherapy for breast cancer; ECOG performance status ≤1 or Karnofsky performace status ≥ 70% Adequate liver/renal function Able to swallow whole tablets. Able to give written informed consent Able to follow prescription instructions reasonably well Exclusion Criteria: Male patient Prior history of other malignancy within 5 years of study entry, aside from contralateral breast carcinoma, appropriately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin Distant metastasis, including skin involvement beyond the breast area Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: observation<br> | |
| Experimental: Everolimus<br> | Drug: Everolimus<br>* 10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measure change of biomarkers in pre- and post- surgery samples |  | baseline and 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
everolimus, neoadjuvant, m-TOR inhibitor
Study Evaluating the Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500

Study Overview
=================
Brief Summary
-----------------
Upon completion of participation in the 6108A1-500 study, subjects will be asked to consent for this duration of immunity study to provide up to two additional blood samples. SBA & IgG testing will be done on these samples taken at 6 & 12 months. The sites participating in this duration of immunity study are the same sites participating in the 6108A1-500 study.

Official Title
-----------------
Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Procedure: Blood Sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Completed study 6108A1-500 (three doses administered and visit 9 completed). Exclusion Criteria: Bleeding diathesis or condition associated with prolonged bleeding time. Any clinically significant chronic disease that, in the investigators judgment may be worsened by blood draw.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br>Includes subjects from a trial involving experimental vaccine and an active comparator vaccine. Comparator is Twinrix (not a MnB vaccine) and thus is comparator for safety but not immunogencity | Procedure: Blood Sampling<br>* Blood draws at 6 and 12 months following end of 6108A1-500 trial.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immunogenicity at 6 and 12 months post 6108A1-500 study. |  | 6 and 12 months |